Entries |
Document | Title | Date |
20080214440 | VASOACTIVE INTESTINAL POLYPEPTIDE COMPOSITIONS - Pharmaceutical compositions relating to vasoactive intestinal polypeptides and methods for the treatment of metabolic disorders, including diabetes, insulin resistance, metabolic acidosis and obesity are presented. Methods of using the vasoactive intestinal polypeptide compositions are also disclosed. | 09-04-2008 |
20080214441 | INSULINS COMBINATIONS - A pharmaceutical association or combination comprising a therapeutic effective amount of insulin or insulin analogue, and a therapeutic effective amount of a pharmaceutically acceptable betaine, in which the insulin and the betaine possibly form a chemical entity or complex, and in which the amount of betaine is adapted for controlling the degradation and/or for increasing the duration of action and/or for enhancing the therapeutically effect of the insulin or insulin analogue. | 09-04-2008 |
20080242596 | BENZYLIC GLYCOSIDE DERIVATIVES AND METHODS OF USE - Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition. | 10-02-2008 |
20080248999 | AMYLIN FORMULATIONS - A combined insulin and amylin and/or GLP-1 mimetic formulation has been developed wherein the pH of the insulin is decreased so that the amylin and/or GLP-1 remains soluble when mixed together with the insulin. In the preferred embodiment, a bolus insulin is administered by injection before breakfast, providing adequate bolus insulin levels to cover the meal, without producing hypoglycemia after the meal. This can be combined with an adequate basal insulin for 24 hours. Lunch and dinner can be covered by two bolus injections of the insulin and amylin and/or GLP-1 mimetic combination. A GLP-1 mimetic may be combined with either rapid acting or basal insulin formulations. As a result, a patient using the combination formulation therapy may only need to inject half as many times per day. | 10-09-2008 |
20080261863 | Pegylation of Vasoactive Intestinal Peptide (Vip) / Pituitary Adenylate Cyclase Activating Peptide (Pacap) Receptor 2 (Vpac2) Agonists and Methods of Use - This invention relates to modified Vasoactive Intestinal Peptide (VIP)/Pituitary Adenylate Cyclase Activating Peptide (PACAP) Receptor 2 (VPAC2) agonists (VPAC2 agonists) comprising a VPAC2 agonist linked to a polyethylene glycol polymer, as well as related formulations, dosages, and methods of administration thereof for therapeutic purposes. These VPAC2 agonists, compositions, and methods are useful in providing a treatment option for those individuals afflicted with a metabolic disorder such as diabetes, impaired glucose tolerance, metabolic syndrome, or prediabetic states, by inducing glucose-dependent insulin secretion in the absence of the therapeutically limiting side effect of reducing or lowering blood pressure. | 10-23-2008 |
20080261864 | Combination of nateglinide or repaglinide with at least one further antidiabetic compound - The present invention relates to a combination of organic compounds which comprises at least two antidiabetic agents, preferably with different modes of action, in which the active ingredients are in each case present in free form or in the form of a pharmaceutically acceptable salt and, optionally, at least on pharmaceutically acceptable carrier, for simultaneous, separate or sequential use. | 10-23-2008 |
20080269110 | NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS - The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I | 10-30-2008 |
20080274947 | Hydroxy-Substituted Diphenylazetidinones for the Treatment of Hyperlipidemia - The present invention comprises compounds and compositions for the treatment of metabolic disorders and more particularly, those insulin-related metabolic disorders of the blood such as hyperlipidemia, diabetes, insulin-resistance and the like comprising diphenylazetidinones compounds which have an additional hydroxy function in the 2″ position and their salts. The invention therefore relates to compounds of formula I: | 11-06-2008 |
20080280814 | Pharmaceutical Compositions Containing Insulin and Insulinotropic Peptide - Pharmaceutical composition for parenteral administration comprising insulin peptide an insulinotropic peptide and a ligand for the His | 11-13-2008 |
20080280815 | Lowering Serum Lipids - The present invention relates to a method for lowering serum lipids, eg. triglycerides and/or cholesterol in a subject comprising administering a GLP-1 agonist to said subject. | 11-13-2008 |
20080280816 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR HEALING WOUNDS - A pharmaceutical composition and method for inducing or accelerating a healing process of a skin wound are described. The pharmaceutical composition contains, as an active ingredient, a therapeutically effective amount of at least one agent for modulating PKC production and/or activation, and a pharmaceutically acceptable carrier. The method is effected by administering the composition to a wound. | 11-13-2008 |
20080280817 | MODIFIED AMINO ACID FOR THE INHIBITION OF PLATELET AGGREGATION - A method of inhibiting blood platelet aggregation in a mammal is provided. The method comprises the administration of a platelet aggregation inhibiting amount of a modified amino acid or pharmaceutically acceptable salt thereof. | 11-13-2008 |
20080293618 | CYCLOPROPYL-FUSED PYRROLIDINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS - The present invention relates to DP IV-inhibitors of formula (1) | 11-27-2008 |
20080300171 | Use of Dpp-IV Inhibitor to Reduce Hypoglycemic Events - The invention relates to a method to reduce the hypoglycemic events, especially sever hypoglycemic events resulting from insulin treatment, wherein the patient is treated with a Dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor) or a pharmaceutically acceptable salt thereof. | 12-04-2008 |
20080300172 | Method and Compositions for the Treatment of Diabetes and Related Complications - The present invention relates to administration of relaxin and related polypeptides to treat a variety of conditions, including diabetes, diabetes-related conditions, Alzheimer's disease, and menopause and related conditions. | 12-04-2008 |
20090005293 | Methods and compositions for increasing the anaerobic working capacity in tissues - Provided are compositions comprising beta-alanylhistidine peptides and beta-alanines, and methods for administering these peptides and amino acids. In one aspect, the compositions and methods cause an increase in the blood plasma concentrations of beta-alanine and/or creatine. | 01-01-2009 |
20090011976 | Stable Formulations Of Peptides - Stable pharmaceutical composition comprising insulinotropic peptide and basal insulin. | 01-08-2009 |
20090018052 | Treatment of Diabetes and Related Pathologies - Methods for treating diabetes mellitus and related conditions and symptoms are described. The methods are directed to administering a therapeutically effective amount of a compound. Compounds suitable for the invention include pyridoxal-5′-phosphate, pyridoxal, pyridoxamine, pyridoxine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof. Also disclosed are methods directed to concurrently administering a therapeutically effective amount of a compound with other compounds known in the treatment of diabetes mellitus. In one embodiment, a therapeutically effective amount of a compound is administered concurrently with a therapeutically effective amount of insulin. In another embodiment, a therapeutically effective amount of a compound is administered concurrently with a therapeutically effective amount of a hypoglycemic compound. | 01-15-2009 |
20090018053 | FORMULATIONS FOR AMYLIN AGONIST PEPTIDES - The present invention is concerned with a pharmaceutical formulation comprising an amylin agonist and optionally a buffer, a tonicifier or stabilizer, and a preservative in a container, for example, a vial, prefilled cartridge, prefilled syringe or disposable pen. This formulation may be in liquid, gel, solid or powdered form for delivery, for example, via nasal, pulmonary, oral, sublingual, buccal, transdermal, or parenteral routes. Formulation with biocompatible polymers and release modifiers, such as sugars, can facilitate controlled release after injection, minimizing the number of administrations to a patient. These formulations maintain stability upon storage under refrigerated or room temperature conditions. Such formulations can be further combined with insulin for administration to a patient. | 01-15-2009 |
20090018054 | Cholesteryl Ester Transfer Protein Inhibitors - Compounds of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), A | 01-15-2009 |
20090018055 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS - Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. These novel compounds have the structure: | 01-15-2009 |
20090018056 | Heteroarylcarbamoylbenzene derivatives - Compounds having glucokinase activating effects and being useful as treatments for diabetes, which are represented by the following formula (I): | 01-15-2009 |
20090029903 | 1,1'-(1,2-Ethynediyl)Bis-Benzene Derivatives As Ptp 1-B Inhibitors - The present invention is related to carboxylic acids of Formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of carboxylic acids of Formula (I) to modulate, notably to inhibit the activity of PTPs. | 01-29-2009 |
20090029904 | Compositions and methods for treatment of insulin-resistance diseases - Compositions and methods are provided for modulation of Target of Rapamycin (TOR) activity. Reduction of TOR blocks insulin resistance and metabolic syndrome phenotypes caused by expression of a constitutively activated version of the insulin responsive transcription factor, FOXO. These TOR-mediated responses are also linked with protection against age-dependent functional organ senescence, e.g., heart decline, as well as increased longevity without changes in resistance to starvation and oxidative stresses. | 01-29-2009 |
20090029905 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES - Compounds of formula (I) | 01-29-2009 |
20090036355 | Antisense Modulation of PTP1B Expression - Compositions and methods are provided for decreasing blood glucose levels in an animal or for preventing or de-laying the onset of a rise in blood glucose levels in an animal, comprising administering to said animal an antisense inhibitor of PTP1B expression in combination with at least one glucose-lowering drug. The present invention is also directed to compositions and methods for improving insulin sensitivity in an animal or for preventing or delaying the onset of insulin resistance in an animal. Also provided are compositions and methods for treating or preventing a metabolic condition in an animal. The metabolic condition may be, e.g., diabetes or obesity. | 02-05-2009 |
20090036356 | Octanoic acid derivatives as dipeptidyl peptidase inhibitors - The present invention is directed to novel Octanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, particularly in the treatment of type 2 diabetes and conditions that are associated with the same. In addition, the present invention provides pharmaceutical compositions useful in inhibiting DPP-IV enzyme, comprising a therapeutically effective amount of Octanoic acid derivatives. Moreover, the present invention provides a method of inhibiting DPP-IV comprising administering to a mammal in need of such treatment a therapeutically effective amount of a single or a combination of Octanoic acid derivatives of the invention. | 02-05-2009 |
20090042772 | COMPOUNDS AND METHODS OF TREATING INSULIN RESISTANCE AND CARDIOMYOPATHY - Novel compounds, compositions comprising compounds, and methods for methods for preparing and using compounds are described herein. Methods of treating or ameliorating various conditions, including insulin resistance, pancreatic beta cell apoptosis, obesity, pro-thrombotic conditions, myocardial infarction, hypertension, dyslipidemia, manifestations of Syndrome X, congestive heart failure, inflammatory disease of the cardiovascular system, atherosclerosis, sepsis, type 1 diabetes, liver damage, and cachexia, by administering compounds described herein. Compounds presented herein may be used to modulate serine palmitoyl transferase activity. | 02-12-2009 |
20090048153 | COMPOSITION FOR TREATING SULFUR MUSTARD TOXICITY AND METHODS OF USING SAME - One embodiment of the present invention provides a composition, comprising, in amounts effective to treat sulfur mustard or half sulfur mustard induced toxicity or skin damage: an agent that inhibits alkylation of —SH and >NH protein groups; an agent that reduces —SS— to SH; a scavenger of reactive oxygen species; a substrate that maintains tissue reduction-oxidation status; an agent that protects against invading inflammatory cells and associated oxidative stress; an antagonist of prostaglandin synthesis; and an agent that induces tissue regeneration. Methods of using the composition are also provided. | 02-19-2009 |
20090048154 | Compositions and Methods for Treating Diabetes - The subject invention provides compositions and methods for treating diabetes in patients. In a preferred embodiment, the invention provides compositions methods for treating diabetes and/or preventing or alleviating complications associated with diabetes. Specifically exemplified herein is the concurrent administration of a cysteamine compound with at least one additional therapeutic agent to prevent and/or treat diabetes as well as prevent and/or treat complications associated with diabetes. In a preferred embodiment, oral administration of cysteamine hydrochloride with Metformin to a patient diagnosed with diabetes can substantially regulate the patient's glucose metabolism and insulin sensitivity. | 02-19-2009 |
20090054303 | CRYSTAL FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING SAME - Physical crystal structures of a compound of the formula I: | 02-26-2009 |
20090054304 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE - The present invention relates to compounds useful as modulators of TGR5 and methods for the treatment or prevention of metabolic, cardiovascular, and inflammatory diseases. | 02-26-2009 |
20090054305 | Mixtures of Amylin and Insulin - The present invention relates to a soluble pharmaceutical composition for parenteral administration, which comprises an amylin peptide, and a meal-related insulin peptide, and to the use of such compositions for treatment of e.g. hyperglycemia. | 02-26-2009 |
20090069216 | Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof - The present invention is related to fast acting single-chain insulin comprising a modified B-chain and the A-chain of human insulin or an analogue thereof connected by a connecting peptide wherein one or more of the amino acid residues in position B25, B26 or B27 in the human B-chain are Glu or Asp or are deleted and/or B28 is Glu, Asp, Lys or is deleted, and the amino acid residue in position B10 in the human insulin B-chain is Gln, Ala, Val, Thr or Ser. The invention is also related to pharmaceutical compositions being a mixture of the rapid acting single-chain insulin and the protracted acylated insulin. | 03-12-2009 |
20090075864 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS - Combination therapy comprising RXR modulators and glucose reabsorption inhibitors useful for the treatment of diabetes and Syndrome X are disclosed. | 03-19-2009 |
20090082256 | CONCOMITANT PHARMACEUTICAL AGENTS AND USE THEREOF - A concomitant agent to be used simultaneously or separately, comprising a combination of (a) 3-{(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine, a salt of the compound with an organic or inorganic and mono- or di-basic acid or a solvate thereof, and | 03-26-2009 |
20090088368 | COMPOSITIONS COMPRISING THEM AS PPAR MODULATORS - The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families. | 04-02-2009 |
20090088369 | GLP-1 AND METHODS FOR TREATING DIABETES - The present invention relates to use of GLP-1 or a related molecule having a GLP-effect for the manufacture of a medicament for preventing or treating diabetes in a mammal. The amount and timing of administration of said medicament are subsequently reduced to produce a “drug holiday.” Practice of the invention achieves effective therapy without continuous drug exposure and without continuous presence of therapeutic levels of the drug. The invention also discloses a method of treating diabetes and related disorders in a mammal by administering glucagon like peptide (GLP-1) or a related molecule having GLP-1 like effect and thereby providing a therapeutically effective amount of endogenous insulin. | 04-02-2009 |
20090105122 | Selective neuropeptide y2 receptor agonists - This invention provides peptides that act as selective NPY2 receptor agonists in vitro and are efficacious in vivo to reduce food intake. The invention is a peptide selected from a specific group of derivatized NPY-related peptides, or functional equivalents thereof. The invention is also directed to a method of treating a metabolic disease in a mammal comprising administering a therapeutically effective amount of the peptides to said mammal to reduce food intake and body weight. | 04-23-2009 |
20090105123 | METHODS FOR THE TREATMENT OF MUSCLE LOSS - The invention provides methods for treating muscle loss in an individual. In one embodiment, the invention includes administering to an individual an effective amount of a branched chain amino acid (BCAA), a BCAA precursor, a BCAA metabolite, a BCAA-rich protein, a protein manipulated to enrich the BCAA content or any combination thereof. The invention further provides nutritional products for such administration, including orally-administrable nutritional products | 04-23-2009 |
20090105124 | HETEROCYCLIC MODULATORS OF TGR5 - Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulation of TGR5 activity in a human or animal subject are also provided for the treatment diseases mediated by TGR5. | 04-23-2009 |
20090105125 | Methods of Treating Fatty Liver Disease - The disclosure provides methods for treating fatty liver disease and associated conditions by inhibiting the synthesis of glucosphingolipids, as exemplified by the use of glucosylceramide synthase substrate analogs. | 04-23-2009 |
20090118159 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES - Compounds of formula (I) | 05-07-2009 |
20090118160 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE - Compounds of the formula | 05-07-2009 |
20090137456 | GLUCAGON ANALOGS EXHIBITING PHYSIOLOGICAL SOLUBILITY AND STABILITY - Modified glucagon peptides are disclosed having improved solubility and stability, wherein the native glucagon peptide has been modified by pegylation, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, or both. | 05-28-2009 |
20090137457 | Pyrimidinedione derivatives - This invention relates to novel compounds that are pyrimidinedione derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel pyrimidinedione derivatives that are derivatives of alogliptin. This invention also provides compositions comprising one or more compounds of this invention and a carrier, and the use of the disclosed compound and compositions in methods of treating diseases and conditions that are beneficially treated by administering a dipeptidyl peptidase IV (DPP4) inhibitor. | 05-28-2009 |
20090143279 | Methods and compositions for treating metabolic disorders - The present invention provides methods of treating of disorders characterized by defective mitochondrial activity. In particular compounds of the present invention can be used in the treatment metabolic diseases and neurodegenerative diseases. The methods are also useful to increase oxidative phosphorylation or to decrease reactive oxygen species (ROS) production in a subject in need thereof. | 06-04-2009 |
20090156465 | DERIVATIVES OF BETA-AMINO ACID AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS - The present invention relates to β-amino acid derivatives as dipeptidyl peptidase-IV inhibitors and the processes for the synthesis of the same. This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating diabetes, especially type 2 diabetes, as well as prediabetes, diabetic dyslipidemia, metabolic acidosis, ketosis, satiety disorders, and obesity. These inhibitors can also be used to treat conditions manifested by a variety of metabolic, neurological, anti-inflammatory, and autoimmune disorders like inflammatory disease, multiple sclerosis, rheumatoid arthritis; viral, cancer and gastrointestinal disorders. The compounds of this invention can also be used for treatment of infertility arising due to polycystic ovary syndrome. | 06-18-2009 |
20090170750 | Single-Chain Insulin - The present invention is related to single-chain insulin having insulin activity comprising a B- and an A-chain or a modified B- and A-chain connected by a connecting peptide of from 6-11 amino acids. The single-chain insulins will have biological insulin activity and an IGF-1 receptor affinity similar to or lower than that of human insulin and a high physical stability. The single-chain insulin may contain at least one basic amino acid residues in the connecting peptide. The single-chain insulins may also be acylated in one or more Lys residues. | 07-02-2009 |
20090176692 | AMIDATED INSULIN GLARGINE - The invention relates to insulin glargine which is modified by amidation, especially Gly (A21), Arg (B31), Arg amide (B32) human insulin (insulin glargine amide). | 07-09-2009 |
20090192074 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR HEALING WOUNDS - A pharmaceutical composition and method for inducing or accelerating a healing process of a skin wound are described. The pharmaceutical composition contains, as an active ingredient, a therapeutically effective amount of at least one agent for modulating PKC production and/or activation, and a pharmaceutically acceptable carrier. The method is effected by administering the composition to a wound. | 07-30-2009 |
20090192075 | Amylin Formulations - A combined insulin and amylin and/or GLP-1 mimetic formulation has been developed wherein the pH of the insulin is decreased so that the amylin and/or GLP-1 remains soluble when mixed together with the insulin. In the preferred embodiment, a bolus insulin is administered by injection before breakfast, providing adequate bolus insulin levels to cover the meal, without producing hypoglycemia after the meal. This can be combined with an adequate basal insulin for 24 hours. Lunch and dinner can be covered by two bolus injections of the insulin and amylin and/or GLP-1 mimetic combination. A GLP-1 mimetic may be combined with either rapid acting or basal insulin formulations. As a result, a patient using the combination formulation therapy may only need to inject half as many times per day. | 07-30-2009 |
20090197794 | Methods of Diagnosing and Treating an Inflammatory Response - The present invention relates to the discovery that VEGF, PlGF, and sFlt-1 levels are increased in inflammatory response such as in sepsis, severe sepsis, or septic shock. Additionally, the invention provides methods of identifying treatments as well as providing treatments for such an inflammatory response, which include decreasing VEGF or PlGF levels, or increasing sFlt- | 08-06-2009 |
20090197795 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY - This invention relates to certain aryl alkyl acid compounds, compositions, and methods for treating or preventing obesity and related diseases. | 08-06-2009 |
20090203577 | Azepinoindole Derivatives As Pharmaceutical Agents - The present invention relates to compounds of formula I, which exhibit affinity for the farnesoid X receptor. | 08-13-2009 |
20090203578 | CERTAIN CRYSTALLINE DIPHENYLAZETIDINONE HYDRATES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR USE - Provided are certain crystalline hydrates of the formula I | 08-13-2009 |
20090215669 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETES - The present invention relates to a composition comprising a peptide of the formula: (Xaa) | 08-27-2009 |
20090239785 | Insulin Derivative - The present invention relates to novel human insulin derivatives which are soluble at physiological pH values and have a prolonged profile of action. The invention also relates to methods of providing such derivatives, to pharmaceutical compositions containing them, to methods of treating diabetes and hyperglycaemia using the insulin derivatives of the invention and to the use of such insulin derivatives in the treatment of diabetes and hyperglycaemia. | 09-24-2009 |
20090253614 | ORAL INSULIN THERAPIES & PROTOCOL - Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing β-cell function, aiding in preventing β-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired glucose tolerance or diabetes, comprising orally administering insulin and a delivery agent that facilitates insulin absorption from the gastrointestinal tract at the time of or shortly before mealtime, e.g., within about 10 minutes prior to ingestion of a meal, on a chronic basis. The methods also comprise, in addition to administering a rapid-acting insulin to provide a first insulin peak, administering a slow acting insulin to provide a second insulin peak occurring at a later time but of a longer duration. These methods achieve improved glycemic control without the risks of hypoglycemia, hyperinsulinemia and weight gain and the need for frequent blood glucose monitoring that are normally associated with insulin therapy. | 10-08-2009 |
20090264338 | Inhibitor of Insulin Multimer Formation - An insulin preparation having an ultra-rapid onset of action is provided by adding a substance that interacts with the insulin dimer formation surface or the hexamer formation surface to an insulin solution. The substance exerts its effect by inhibiting insulin dimer formation and/or hexamer formation. | 10-22-2009 |
20090286716 | Soluble Pharmaceutical Compositions for Parenteral Administration Comprising a GLP-1 Peptide and an Insulin Peptide of Short Time Action for Treatment of Diabetes and Bulimia - Pharmaceutical composition for parenteral administration comprising a meal related insulin peptide and an insulinotropic peptide. | 11-19-2009 |
20090298745 | Treatment of Diabetes with Glycogen Phosphorylase Inhibitors - The invention provides a method of treatment of diabetes, particularly type II diabetes, or a diabetes related condition, comprising night time dosing of an inhibitor of glycogen phosphorylase, optionally in combination another anti-diabetic therapy. | 12-03-2009 |
20090312237 | REGULATING FAT AND CARBOHYDRATE OXIDATION IN MUSCLE TISSUE COMPRISING CONTROLLING GARNITINE CONTENT IN MUSCLE - Methods, compositions and substances for regulating fat and carbohydrate oxidation in the muscle tissue of human and/or animal bodies, which involve controlling the carnitine content of the muscle tissue. Regulating carbohydrate and fat oxidation, and particularly increasing the level of fat oxidation in accordance with the present invention, by providing substances compositions and methodologies in accordance with the present invention, enable medicaments to be manufactured and methodologies employed that find use in the treatment of disorders and conditions of the human and/or animal body caused by impairment of the usual level of fat oxidation, including obesity and type 2 diabetes. | 12-17-2009 |
20090318331 | ORAL INSULIN THERAPIES AND PROTOCOL - Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing β-cell function, aiding in preventing β-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired glucose tolerance or diabetes, comprising orally administering insulin and a delivery agent that facilitates insulin absorption from the gastrointestinal tract at the time of or shortly before mealtime, e.g., within about 10 minutes prior to ingestion of a meal, on a chronic basis. The methods also comprise, in addition to administering a rapid-acting insulin to provide a first insulin peak, administering a slow acting insulin to provide a second insulin peak occurring at a later time but of a longer duration. These methods achieve improved glycemic control without the risks of hypoglycemia, hyperinsulinemia and weight gain and the need for frequent blood glucose monitoring that are normally associated with insulin therapy. | 12-24-2009 |
20090318332 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS - The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR modulators to treat or inhibit the progression of, for example, dyslipidemia. | 12-24-2009 |
20100004159 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES - The present invention relates to polysubstituted imidazolone derivatives, to the pharmaceutical compositions comprising them and to the therapeutic uses thereof in the human and animal health fields. The present invention also relates to a process for preparing these derivatives. | 01-07-2010 |
20100004160 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES - This invention relates to substituted fused heterocyclic C-glycosides, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of diabetes and Syndrome X. | 01-07-2010 |
20100009900 | SUBSTITUTED INDOLE-O-GLUCOSIDES - Substituted indole-O-glucosides, compositions containing them, and methods of using them, for example for the treatment of diabetes and Syndrome X are disclosed. | 01-14-2010 |
20100016213 | USE OF A DITERPENOID COMPOUND FOR TREATING DIABETES - A method for lowering the plasma glucose level in a subject and for treating diabetes with a diterpenoid compound. | 01-21-2010 |
20100016214 | CARBOHYDRATES MIXTURE - A carbohydrate mixture for dietetic foods and pharmaceuticals containing several carbohydrates is provided according to the present invention. Said carbohydrate mixture is characterized in that they contain or consist of two different, substantially soluble carbohydrate components A and B, which remain undigested in the gastrointestinal tract and enter the large intestine without being resorbed,
| 01-21-2010 |
20100048454 | Antidiabetic oral insulin-biguanide combination - Pharmaceutical dosage forms, comprising insulin, a delivery agent that facilitates insulin transport in a therapeutically effective amount to the bloodstream and a biguanide, such as metformin, are disclosed for oral administration to a patient for the treatment of diabetes. Also disclosed are methods for achieving improved glucose tolerance and glycemic control in a diabetic mammal without any statistically significant increase in weight, risk of hypoglycemia or hyperinsulinemia, and the need for monitoring blood glucose concentrations or HbAlc levels, and methods for reducing the incidence and/or severity of one or more disease states associated with chronic dosing of insulin; for prophylactically sparing (3-cell function or for preventing (3-cell death or dysfunction in a mammal with impaired glucose tolerance or early stage diabetes mellitus; and for long-term protection from developing (or delaying the onset of) overt or insulin dependent diabetes in a mammal with impaired glucose tolerance or early stage diabetes. | 02-25-2010 |
20100056426 | USE OF IRON CHELATOR FOR THE TREATMENT OF MYOCARDIAL INFARCTION - The present invention relates to a method of treating and/or preventing myocardial infarction comprising administering an iron chelator to a warm-blooded animal. The iron chelator is preferably 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic. | 03-04-2010 |
20100062971 | SUBSTITUTED INDAZOLE-O-GLUCOSIDES - Substituted indazole-O-glucosides, compositions containing them, and methods of using them, for example for the treatment of diabetes and Syndrome X are disclosed. | 03-11-2010 |
20100062972 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO - The present invention provides a triazole compound of the following formula: | 03-11-2010 |
20100075894 | REDUCING ER STRESS IN THE TREATMENT OF OBESITY AND DIABETES - Endoplasmic reticulum stress has been found to be associated with obesity. Therefore, agents that reduce or prevent ER stress may be used to treat diseases associated with obesity including peripheral insulin resistance, hypergylcemia, and type 2 diabetes. Two compounds which have been shown to reduce ER stress and to reduce blood glucose levels include 4-phenyl butyric acid (PBA), tauroursodeoxycholic acid (TUDCA), and trimethylamine N-oxide (TMAO). Other compounds useful in reducing ER stress are chemical chaperones such as trimethylamine N-oxide and glycerol. The present invention provides methods of treating a subject suffering from obesity, hyperglycemia, type 2 diabetes, or insulin resistance using ER stress reducers such as PBA, TUDCA, and TMAO. Methods of screening for ER stress reducers by identifying agents that reduce levels of ER stress markers in ER stressed cells are also provided. These agents may find use in methods and pharmaceutical compositions for treating obesity-associated diseases. | 03-25-2010 |
20100093604 | Gpr43 and modulators thereof for the treatment of metabolic-related disorders - The present invention relates to a method for identifying a metabolic stabilizing compound by: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is modulated, where a modulation in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound. In addition, the invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is increased, wherein an increase in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound. Further, the invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR43, and b) determining whether GPR43 functionality is decreased, wherein a decrease in GPR43 functionality is indicative of the candidate compound being a metabolic stabilizing compound. | 04-15-2010 |
20100093605 | PEPTIDES, DERIVATIVES AND ANALOGS THEREOF, AND METHODS OF USING SAME - Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, and/or lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome. | 04-15-2010 |
20100105604 | ALLYLOXY AND ALKYLOXY BENZOIC ACID DELIVERY AGENTS - The present invention relates to pharmaceutical compounds for delivering active agents, such as biologically or chemically active agents, to a target. The invention also relates to pharmaceutical compositions comprising at least one delivery agent compound of the present invention and at least one active agent, and unit dosage forms comprising such compositions. Methods for the preparation and administration of the pharmaceutical compositions are also disclosed. | 04-29-2010 |
20100105605 | FATTY ACID FORMULATIONS AND ORAL DELIVERY OF PROTEINS AND PEPTIDES, AND USES THEREOF - Fatty acid compositions for administration of of pharmaceutical agents, such as proteins and peptides, protein and peptide conjugates, and/or cation-polypeptide conjugate complexes. In particular, the invention provides a solid pharmaceutical composition formulated for oral administration by ingestion, having from about 0.1 to about 75% w/w fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent. Further, the invention provides a liquid pharmaceutical composition formulated for oral administration by ingestion, comprising: from about 0.1 to about 10% w/v fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent. | 04-29-2010 |
20100113330 | TETRAHYDROPYRIDO[4,3-D]PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to methods of using Tetrahydropyrido[4,3-d]Pyrimidinone Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR119 in a patient. | 05-06-2010 |
20100113331 | Substituted Imidazole Derivatives, Compositions, and Methods of Use as PtPase Inhibitors - The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes. | 05-06-2010 |
20100120662 | Glucose uptake modulator and method for treating diabetes or diabetic complications - The present invention relates to an glucose uptake modulator, a pharmaceutical composition comprising the glucose uptake modulator, and a method of treating a diabetes or diabetic complications in a mammal in need thereof, which comprises administering to said mammal an effecting amount of a glucose uptake modulator. | 05-13-2010 |
20100130403 | Biomarkers for insulin efficacy - The invention provides compositions and methods for determining insulin efficacy in a subject. The invention also provides compositions and methods for treating a subject according to the efficacy of insulin in the subject. | 05-27-2010 |
20100130404 | Biomarkers for cardiodiabetes - The invention provides compositions and methods for determining cardiodiabetes status in a subject. The invention also provides compositions and methods for treating a subject experiencing cardiodiabetes. | 05-27-2010 |
20100144594 | 2-HETEROARYL-PYRROLO[3,4-C]PYRROLE DERIVATIVES AND THEIR USE AS SCD INHIBITORS - The invention relates to heterocyclic derivatives of formula I | 06-10-2010 |
20100167986 | Cholesteryl Ester Transfer Protein Inhibitors - Compounds of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), A | 07-01-2010 |
20100167987 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR HEALING WOUNDS - A pharmaceutical composition and method for inducing or accelerating a healing process of a skin wound are described. The pharmaceutical composition contains, as an active ingredient, a therapeutically effective amount of at least one agent for modulating PKC production and/or activation, and a pharmaceutically acceptable carrier. The method is effected by administering the composition to a wound. | 07-01-2010 |
20100167988 | ETHOXYPHENYLMETHYL INHIBITORS OF SGLT2 - The present invention relates to new ethoxyphenylmethyl modulators of SGLT2, pharmaceutical compositions thereof, and methods of use thereof. | 07-01-2010 |
20100167989 | ISOPROPOXYPHENYLMETHYL INHIBITORS OF SGLT2 - The present invention relates to new isopropoxyphenylmethyl inhibitors of SGLT2, pharmaceutical compositions thereof, and methods of use thereof. | 07-01-2010 |
20100167990 | Pharmaceutical Formulations Comprising an Insulin Derivative - The invention concerns a soluble pharmaceutical formulation comprising an insulin derivative wherein the formulation further comprises more than 4 zinc atoms per 6 molecules of the insulin derivative, and a citric acid monohydrate and/or a histidine compound used in an amount sufficient to increase the tendency of the insulin derivative to self-associate into dodecamers. The invention further comprises a process for preparing the soluble pharmaceutical formulation. | 07-01-2010 |
20100173825 | HETEROARYL BENZAMIDE DERIVATIVES - The invention relates to a novel group of compounds of Formula (I) or a salt thereof: | 07-08-2010 |
20100190687 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to Pyrimidinone Derivatives, compositions comprising a Pyrimidinone Derivative, and methods of using the Pyrimidinone Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of G protein-coupled receptor 119 (“GPR119”) in a patient. | 07-29-2010 |
20100210505 | POLYMER CONJUGATES OF GLP-1 - Conjugates of a GLP-I moiety may be covalently attached to one or more water-soluble polymers. For instance, a GLP-I polymer conjugate may include a GLP-I moiety releasably attached at its N-terminus to a water-soluble polymer. The GLP-I polymer conjugate may include a GLP-I moiety covalently attached to a water-soluble polymer, wherein the GLP-I moiety possesses an N-methyl substituent. The GLP-I polymer conjugate may include a GLP-I moiety covalently attached at a polymer attachment site to a water-soluble polymer, wherein the GLP-I moiety is glycosylated at a site separate from the polymer attachment site. | 08-19-2010 |
20100210506 | INTRANASAL ADMINISTRATION OF RAPID ACTING INSULIN - What is described are pharmaceutical compositions, formulations, and uses thereof, for medicaments for intranasal delivery of insulin to a patient, comprising an aqueous mixture of human insulin, a solubilizing agent, and a surface active agent, wherein the human insulin may be rapid actin insulin. | 08-19-2010 |
20100216693 | COMPOSITIONS AND METHODS OF TREATING DIABETES - The invention features compositions comprising insulin and C-peptide and methods for treating diabetes, using such compositions. The invention further features compositions comprising insulin analogues and C-peptide and the uses thereof for treating diabetes. | 08-26-2010 |
20100216694 | ANTIDIABETIC TRICYCLIC COMPOUNDS - Tricyclic compounds containing a cyclopropanecarboxylic acid fused to a bicyclic ring, including pharmaceutically acceptable salts, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. | 08-26-2010 |
20100222251 | MIXTURE COMPRISING AN AMYLIN PEPTIDE AND A PROTRACTED INSULIN - The invention relates to a soluble pharmaceutical composition for parenteral administration, which comprises an amylin peptide and a protracted insulin peptide. | 09-02-2010 |
20100227797 | USE OF CYCLOLIGNANS FOR THE TREATMENT OF TYPE 2 DIABETES AND AS CONTRACEPTIVES - There is disclosed use of certain cyclolignans for prophylaxis or treatment of diabetes mellitus type 2, nephropathy, retinopathy, macular degeneration, retinopathy of prematurity, central retinal vein occlusion, branch retinal vein occlusion, rubeotic glaucoma, thyroid eye disease, corneal graft rejection and corneal chemical burns; and for contraception. Preferred compounds are picropodophyllin, deoxypicropodophyllin and anhydropicropodophyllol. There is also described a method of treatment of an eye disease. | 09-09-2010 |
20100234274 | Use of Nestafin-1 in the Treatment for Diabetes - The present invention provides a method of treating diabetes by increasing peripheral nesfatin-1. Peripheral nesfatin-1 can be increased by administration of nesfatin-1, conjugated nesfatin-1 that would not penetrate the blood-brain barrier, or plasmin inhibitors. The present invention also provides a method of screening for an agent that would increase peripheral or brain nesfatin-1. | 09-16-2010 |